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Diseased skin often exhibits a deregulated program of the keratinocyte maturation necessary for epidermal strat-
iﬁcation and function. Protein kinase D (PKD), a serine/threonine kinase, is expressed in proliferating keratin-
ocytes, and PKD activation occurs in response to mitogen stimulation in other cell types. We have proposed that
PKD functions as a pro-proliferative and/or anti-differentiative signal in keratinocytes and hypothesized that dif-
ferentiation inducers will downmodulate PKD to allow differentiation to proceed. Thus, changes in PKD levels,
autophosphorylation, and activity were analyzed upon stimulation of differentiation and proliferation in primary
mouse keratinocytes. Elevated extracellular calcium and acute 12-O-tetradecanoylphorbol-13-acetate (TPA) treat-
ments induced differentiation and triggered a downmodulation of PKD levels, autophosphorylation at serine 916,
and activity. Chronic TPA treatment stimulated proliferation and resulted in a recovery of PKD levels, auto-
phosphorylation, and activity. Immunohistochemical analysis demonstrated PKD localization predominantly in the
proliferative basal layer of mouse epidermis. Co-expression studies revealed a pro-proliferative, anti-differentiative
effect of PKD on keratinocyte maturation as monitored by increased and decreased promoter activities of keratin 5,
a proliferative marker, and involucrin, a differentiative marker, respectively. This work describes the inverse reg-
ulation of PKD during keratinocyte differentiation and proliferation and the pro-proliferative/anti-differentiative
effects of PKD co-expression on keratinocyte maturation.
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The skin is the largest organ of the body and acts as a
protective barrier against environmental insults, such as ul-
traviolet radiation, mechanical stress, and water permea-
tion. The skin is also an integral component of the immune,
nervous, and endocrine systems. Keratinocytes, the major
cell type of the epidermis, produce the proteins and lipids
necessary for the barrier function of the skin. Keratinocyte
maturation encompasses a tightly regulated program of
proliferation and terminal differentiation that facilitates ep-
ithelial stratification. As keratinocytes differentiate, they mi-
grate upward through the four layers of the epidermis, the
strata basalis, spinosum, granulosum, and corneum, and
express proteins indicative of their differentiative status. For
example, within the stratum basalis, keratinocytes maintain
a proliferative status and express keratin 5 (Fuchs, 1995).
Within the stratum spinosum, keratinocytes are committed
to terminal differentiation and begin to express cornified
envelope components, such as involucrin (Warhol et al,
1985). Thus, keratin 5 expression is a marker of prolifera-
tion, whereas involucrin expression is a marker of differ-
entiation. Another hallmark of differentiation is trans-
glutaminase activity, which is maximal in the stratum
granulosum and catalyzes the formation of g-glutamyl-e-
lysine bonds that cross-link the cornified envelope proteins
(Thacher and Rice, 1985).
One regulator of the differentiation program of keratin-
ocytes is thought to be elevated extracellular calcium con-
centrations ([Ca2þ ]e). Indeed, keratinocytes are known to
possess a calcium-sensing receptor (CaR), a G protein-
coupled receptor identical to the parathyroid CaR (Hebert
and Brown, 1995; Chattopadhyay et al, 1996). Not only
does the CaR mediate elevated [Ca2þ ]e-induced differen-
tiation in situ (Tu et al, 1999), but the full-length version of
the CaR is necessary for normal epidermal differentiation
(Komuves et al, 2002). Keratinocytes downregulate the CaR
by alternative splicing, which yields an inactive form (Oda
et al, 1998, 2000) as a result of differential glycosylation that
prevents transport to the plasma membrane (Tu et al, 2004).
In normal epidermis, a calcium gradient is maintained such
that the lowest levels exist in the basal layer and the highest
levels are present in the granular layer (Tu et al, 2004). In situ
data correlate keratinocyte growth capacity with this in vivo
gradient. Specifically, keratinocyte cultures maintain a pro-
liferative status when cultured in low calcium concentrations
(0.05–0.09 mM), but intermediate calcium concentrations
Abbreviations: [Ca2þ ]e, extracellular calcium concentration;
125(OH)2D3, 1,25-dihydroxyvitamin D3; C, carboxy; CaR, cal-
cium-sensing receptor; DMSO, dimethyl sulfoxide; Go¨, Go¨decke;
ITSþ , insulin, transferrin, selenous acid, linoleic acid; N, amino;
PBS-, phosphate-buffered saline lacking divalent cations; PKC,
protein kinase C; PKD, protein kinase D; SEM, standard error of the
mean; SFKM, serum-free keratinocyte medium; TPA, 12-O-tetra-
decanoylphorbol-13-acetate
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(0.14–0.29 mM) stimulate focal areas of stratification,
whereas higher calcium concentrations (above 1 mM) in-
duce terminal differentiation (Hennings et al, 1980). Al-
though only qualitative data exist describing the calcium
concentrations in the epidermal layers and the exact mech-
anisms of action of this ion have not been elucidated, the
presence of an extracellular CaR, an in vivo calcium gra-
dient, and in situ effects of elevated calcium concentrations
strongly support the idea that calcium acts as a key reg-
ulator of keratinocyte maturation in vivo.
12-O-tetradecanoylphorbol-13-acetate (TPA), a com-
plete tumor promoter and phorbol ester, causes biphasic
responses in keratinocytes, stimulating differentiation
acutely and proliferation chronically, in situ (Yuspa et al,
1982a) and in vivo (Raick et al, 1972; Argyris, 1980; Toftgard
et al, 1985). Data supporting the ability of TPA to stimulate
terminal differentiation include demonstrations of enhance-
ment of transglutaminase activity (Yuspa et al, 1982a), in-
duction of cornified envelope formation (Parkinson et al,
1984), augmentation of expression of the late differentiative
markers, involucrin (Poumay et al, 1999), loricrin and filag-
grin (Dlugosz and Yuspa, 1993), repression of early differ-
entiation markers, such as Keratins 1 and 10 (Dlugosz and
Yuspa, 1993), and activation of several protein kinase C
(PKC) isoforms (PKC-a, -d, -e, or -Z) implicated in differen-
tiation (Bollag and Bollag, 2001). Conversely, chronic treat-
ment of keratinocytes with TPA stimulates proliferation
in situ (Yuspa et al, 1976, 1982a), and in conjunction with a
DNA-damaging agent, leads to tumor formation in vivo
(Goerttler et al, 1979). This chronic proliferative response
has allowed the use of keratinocyte cultures treated with
TPA as in situ models for mouse tumor formation (Yuspa
et al, 1982b). Yuspa et al (1982a) discovered that approx-
imately half of a population of cultured mouse keratinocytes
are resistant to the differentiative effects of TPA, such that
differentiating cells are sloughed to the environment where-
as proliferating cells are retained. This suggests that the
response of keratinocytes to TPA treatment varies because
of differences in cell cycle or commitment to differentiation.
Also, chronic TPA stimulation causes phorbol ester-respon-
sive PKC to undergo proteolytic degradation, a character-
istic not shared by the distantly related enzyme, protein
kinase D (PKD) (Rennecke et al, 1996). Whether chronic TPA
promotes proliferation or tumor formation through the pro-
teolysis of differentiative PKC, through the activation of
other phorbol ester-responsive enzymes, such as PKD, or
through a combination of these actions, is not known.
PKD, also known as PKCm, was cloned and identified by
two groups using PCR-based strategies to identify novel
protein kinases (Johannes et al, 1994; Valverde et al, 1994).
PKD binds diacylglycerol and phorbol esters, leading to
activation, in vitro and in situ (Valverde et al, 1994; Van Lint
et al, 1995; Dieterich et al, 1996). Sequence analysis iden-
tified regions of similarity to PKC (Johannes et al, 1994), but
the unique characteristics of PKD have led to its distinction
as the first member (i.e., PKD1) of a new family of enzymes,
the PKD family (Valverde et al, 1994; Van Lint et al, 1995),
which now consists of PKCm/PKD1, PKD2, and PKCn/
PKD3. Some of the characteristics that distinguish PKD
from PKC include: the presence of an amino (N) terminal
hydrophobic region, the lack of an autoinhibitory pseudo-
substrate domain, and the increased length of the inter-
vening sequence separating the two C1 domains that also
lack some of the conserved residues found in PKC (Bollag
et al, 2004). Additionally, PKD does not bind or become
activated by calcium, as do classical PKCs, and it contains
a pleckstrin homology domain, which is involved in regu-
lating enzymatic activity, binding of effector proteins, and
maintaining subcellular localization (Bollag et al, 2004). The
catalytic domain of PKD is more homologous to that of the
calcium/calmodulin-dependent protein kinases; therefore,
PKD is able to efficiently phosphorylate the calcium/cal-
modulin-dependent protein kinase synthetic substrate, syn-
tide-2, in vitro (Van Lint et al, 1995; Dieterich et al, 1996). At
the carboxy (C) terminus within the catalytic domain, PKD is
autophosphorylated on the serine residue at position 916,
which correlates with PKD activation (Matthews et al, 1999),
and once activated in situ, PKD retains enzymatic activity
following immunoprecipitation (Rozengurt et al, 1997). The
function of PKD is the subject of active research, but few
bona fide in vivo PKD substrates or downstream effector
proteins have been convincingly demonstrated (Rykx et al,
2003). Even less is known about the function of the PKD
family members, PKD2 and PKD3.
PKD (i.e., PKD1) has been implicated in mitogenesis in
multiple cell types. PKD is activated following exposure
of cells to a variety of mitogens, such as platelet-derived
growth factor, bombesin, vasopressin, endothelin, brad-
ykinin, lysophosphatidic acid, thrombin, angiotensin II, and
neurotensin (Bollag et al, 2004). When overexpressed in
Swiss 3T3 cells, PKD potentiates DNA synthesis and cell
proliferation in response to treatment with phorbol esters
and the Gq-protein-coupled receptor agonists, bombesin
and vasopressin (Zhukova et al, 2001). This potentiation of
DNA synthesis in response to G protein-coupled receptor
agonists is thought to be facilitated by the ability of active
PKD to increase the duration of extracellular-regulated pro-
tein kinase-1 and -2 activation (Sinnett-Smith et al, 2004). In
mouse keratinocytes, PKD has been discovered at higher
concentrations in proliferative cell fractions, and PKD levels
are increased in carcinomas isolated from mouse epidermis
(Rennecke et al, 1999). Studies using the classical PKC/
PKD inhibitor Go¨decke (Go¨) 6976 have demonstrated that
the inhibition of both classical PKC and PKD stimulates
keratinocyte differentiation. In contrast, Go¨ 6983, which in-
hibits classical PKC but not PKD at the concentrations
used, does not stimulate differentiation (Shapiro et al, 2002).
These results support the idea that Go¨ 6976, but not Go¨
6983, induces differentiation because of its inhibition of a
pro-proliferative and/or anti-differentiative signal. The use of
a panel of inhibitors suggests that the pro-proliferative/anti-
differentiative signal is PKD (Shapiro et al, 2002), as we have
recently proposed (Bollag et al, 2004). We also predict that
agents that stimulate keratinocyte differentiation, such as
elevated [Ca2þ ]e or acute TPA treatment, will downregulate
PKD expression and/or activity to allow differentiation to
proceed.
Herein, we describe the regulation of PKD protein levels,
autophosphorylation, and activity following treatment of
primary mouse keratinocyte cultures with the differentiation-
promoting agents, elevated [Ca2þ ]e and acute TPA treat-
ment (p8 h), and the proliferation-promoting agent, chronic
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TPA treatment (424 h). PKD protein levels, auto-
phosphorylation, and activity were downmodulated upon
commitment to the differentiation program. Conversely, a
recovery of PKD occurred in conjunction with proliferation.
By immunohistochemical analysis, the distribution of PKD
protein expression in intact neonatal mouse epidermis was
found to be highest in the basal layer, the proliferative layer.
Finally, PKD co-expression affected keratinocyte maturation
status in a pro-proliferative/anti-differentiative manner.
Results
Treatment of keratinocytes with elevated extracellular
calcium and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3)
causes apparent decreases in PKD protein levels In
order to evaluate the regulation of PKD in mouse kera-
tinocytes, PKD protein levels were analyzed following
treatment of cultures with the differentiation-promoting
agents, elevated [Ca2þ ]e and 1,25(OH)2D3. We have
proposed that PKD is a pro-proliferative and/or anti-differ-
entiative signal in keratinocytes (Bollag et al, 2004) and have
hypothesized that agents that stimulate keratinocytes to
differentiate might also initiate a reduction in PKD expres-
sion and/or activation to allow differentiation to proceed.
Therefore, near-confluent cultures of keratinocytes were in-
cubated for 24 h in serum-free keratinocyte medium (SFKM)
(25 mM CaCl2) containing vehicle (0.05% ethanol), 1 mM
CaCl2 (þ0.05% ethanol), or 250 nM 1,25(OH)2D3. After
treatment, samples were collected for western blot analysis,
and the immunoreactive signals obtained using a C-termi-
nus-specific PKD antibody, SC-935, and an 125I-labeled
secondary antibody were quantified. Both calcium and
1,25(OH)2D3 treatment caused significant decreases in the
PKD signal, 27%  2.32% and 25%  8.76%, respectively
(Fig 1A,B). These results could be interpreted as a reduction
of PKD in conjunction with differentiation, or alternatively, as
reduced antigen recognition by the SC-935 antibody for
PKD because of a change in the conformation or phos-
phorylation status of PKD following treatment. Another
C-terminus-specific PKD antibody, SC-639, is known to
exhibit reduced recognition of PKD once PKD becomes
phosphorylated/activated (Rennecke et al, 1996).
Acute treatment of keratinocytes with TPA causes ap-
parent decreases in PKD protein levels but increases
PKD activity To investigate the possibility that the recog-
nition of PKD by the SC-935 antibody is affected by the
phosphorylation/activation status of PKD, PKD protein lev-
els were analyzed following short-term treatment of cultures
with TPA. TPA is a phorbol ester known to activate and
increase the autophosphorylation status of PKD (Rennecke
et al, 1996; Zugaza et al, 1996). Near-confluent cultures of
keratinocytes were incubated for 10 min in SFKM (25 mM
CaCl2) containing vehicle (0.1% dimethyl sulfoxide (DMSO))
or 100 nM TPA, and samples were collected for western blot
analysis and signal quantification. Surprisingly, the TPA
treatment caused a 53%  7.8% decrease in the PKD sig-
nal, suggesting an apparent reduction in total PKD levels at
this early time point (Fig 2A,B). The data were interpreted to
mean that SC-935 exhibits reduced recognition of phos-
phorylated/activated PKD for the following reasons: (1) the
short treatment time suggests that downregulation is un-
likely; (2) reports describe the lack of downregulation of
PKD following TPA treatment (Rennecke et al, 1996); and (3)
TPA is known to activate and induce the autophosphorylat-
ion of PKD in keratinocytes (Rennecke et al, 1996) and in
other cell types (Zugaza et al, 1996).
To verify that TPA activates PKD in our system, keratin-
ocyte cultures were incubated in SFKM (25 mM CaCl2) con-
taining vehicle (0.1% DMSO) or 100 nM TPA for 10 min. PKD
was immunoprecipitated using two primary antibodies si-
multaneously: one targeting the N-terminus, SC-638, and
one targeting the C-terminus, SC-935. TPA stimulation fol-
lowed by incubation of immunoprecipitated PKD with syn-
tide-2 in the presence of [g-32P]adenosine triphosphate
([g-32P]ATP) produced a significant 3.3  0.41-fold increase
in phosphorylation of syntide-2 (Fig 2C), as well as an in-
crease in PKD autophosphorylation (data not shown). The
data verified that PKD is indeed activated by TPA in kera-
tinocytes and support the interpretation that SC-935 exhibits
reduced recognition of phosphorylated/activated PKD.
Commercially available PKD-specific antibodies vary in
their recognition of PKD Because the SC-935 antibody
seemed inappropriate for our studies, we investigated the
antigen recognition of several alternative commercially
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Figure1
Elevated extracellular calcium and 1,25-dihydroxyvitamin D3 in-
duce apparent decreases in protein kinase D (PKD) protein levels.
Primary keratinocytes were incubated for 24 h in serum-free keratin-
ocyte medium containing vehicle (0.05% ethanol) (Control, open bar),
1 mM CaCl2 (þ0.05% ethanol) (1 mM Ca2þ , hatched bar) or 250 nM
(250 nM D3, striped bar). After lysis and collection, samples were loaded
according to protein concentration and subjected to western blot anal-
ysis. (A) The immunoreactive signals obtained using SC-935 and an
125I-labeled secondary antibody were visualized using a Phosphorim-
ager SI and (B) were quantified by ImageQuant software and analyzed
using Instat 2.0. Values represent the means  standard error of the
mean from four separate experiments versus the control and were
analyzed by ANOVA with significance at po0.05 ().
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available PKD-specific antibodies. COS-7 cells were trans-
fected with either the empty vector control, pcDNA3, or the
PKD expression vector, pcDNA3–PKD. After lysis and col-
lection, 10 mg of protein were loaded in quadruplicate and
was subjected to western blot analysis using the PKD-spe-
cific antibodies: SC-935, SC-638, CS-2052, and CS-2051.
(The SC-639 antibody was not tested because of previous
reports of this antibody exhibiting reduced recognition of
activated/phosphorylated PKD (Rennecke et al, 1996)).
Each antibody tested (SC-935, SC-638, CS-2052, and
CS-2051) produced a strong immunoreactive signal when
PKD was transiently overexpressed compared with empty
vector control (pcDNA3) (Fig 3). The SC-638 antibody pro-
duced the weakest immunoreactive signal, which suggest-
ed a less efficient recognition of PKD, and previous
results (Fig 2) rendered the SC-935 antibody suspect for
western analyses. Based on these results, the CS-2052 and
CS-2051 antibodies were used for our subsequent western
analyses.
PKD protein levels are not decreased following acute
treatment of keratinocytes with TPA Previous reports
have demonstrated that serine 916 of PKD becomes phos-
phorylated in response to phorbol esters, and this
phosphorylation status correlates with enzymatic activity
(Matthews et al, 1999). This was corroborated in our sys-
tem by syntide-2 phosphorylation assays; therefore, the
decreased signals corresponding to PKD protein levels
were interpreted as decreases in the recognition of the SC-
935 antibody for phosphorylated activated PKD. Therefore,
we re-examined the effects of acute 100 nM TPA treatments
on PKD protein levels using two alternate primary antibod-
ies obtained from Cell Signaling Technology: one targeting
the C-terminus of PKD, CS-2052, and one targeting the
autophosphorylated serine 916 residue, CS-2051. Near-
confluent primary keratinocyte cultures were treated with
100 nM TPA for 10 min, and samples were collected for
western blot analysis. Interestingly, no apparent decrease in
PKD protein levels was observed when using CS-2052; yet,
a large increase in signal occurred when using CS-2051,
suggesting an increase in phosphorylation at serine 916
(Fig 4). These data suggest that the SC-935 antibody prefer-
entially recognizes the unphosphorylated form of PKD, as
previously reported of the SC-639 antibody (Rennecke et al,
1996). Thus, the previous conclusion that PKD protein levels
were downmodulated following elevated [Ca2þ ]e- and
1,25(OH)2D3-induced differentiation of primary keratin-
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Figure 2
12-O-tetradecanoylphorbol-13-acetate (TPA) induces apparent de-
creases in protein kinase D (PKD) protein levels but stimulates
PKD activity. Primary keratinocytes were incubated for 10 min in se-
rum-free keratinocyte medium containing vehicle (0.1% dimethyl sulf-
oxide) (Control, open bar) or 100 nM TPA (100 nM TPA, striped bar).
(A,B) After lysis and collection, samples were loaded according to
protein concentration and subjected to western blot analysis. (A) The
immunoreactive signals obtained using SC-935 and an 125I-labeled
secondary antibody were visualized using a Phosphorimager SI and (B)
were quantified by ImageQuant software and analyzed using In Stat
2.0. Values represent the means  standard error of the mean (SEM)
from four experiments versus the corresponding control and were
analyzed by a Student’s t test with significance at po0.05 (). (C) PKD
was immunoprecipitated using both SC-638 and SC-935, simultane-
ously, and protein-A agarose. The immunoprecipitate was incubated
with syntide-2 in the presence of [g-32P]adenosine triphosphate, and
the resulting phosphorylation was measured in a scintillation counter.
Values represent the means  SEM from three separate experiments
versus the respective corresponding control and were analyzed by a
Student’s t test with significance at po0.05 ().
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Figure3
Commercial protein kinase D (PKD)-specific antibodies recognize
PKD overexpressed in COS-7 cells. COS-7 cells were transfected
with pcDNA3 (lanes 1, 3, 5, and 7) or pcDNA3-PKD (lanes 2, 4, 6, and
8). After lysis and collection, equal protein amounts (10 mg) from each
sample were loaded in quadruplicate and subjected to western blot
analysis. The immunoreactive signals were obtained using PKD-spe-
cific antibodies (SC-935, SC-638, CS-2052, or CS-2051) and a sec-
ondary antibody conjugated with alkaline phosphatase. The signals
were visualized using a Storm Phosphorimager. Actin was used as a
control to verify equal loading.
133
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Figure4
Acute 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment
does not induce decreases in protein kinase D (PKD) protein lev-
els. Primary keratinocytes were incubated for 10 min in serum-free
keratinocyte medium containing vehicle (0.005% dimethyl sulfoxide)
(Control) or 100 nM TPA (TPA). After lysis and collection, samples were
loaded according to protein concentration and subjected to western
blot analysis. The immunoreactive signals were obtained using either
CS-2052 (PKD) or CS-2051 (Phospho-PKD S916) and a secondary
antibody conjugated with horseradish peroxidase. The signals were
visualized after exposure to film using enhanced chemiluminescence,
and the figure is a representative blot of four experiments.
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ocytes was rendered suspect. Additionally, the results sug-
gested that the recognition of PKD by the CS-2052 antibody
is not affected by PKD phosphorylation status (Fig 4).
Treatment of keratinocytes with elevated extracellular
calcium causes a reduction in PKD protein levels, au-
tophosphorylation, and activity Because the SC-935 an-
tibody exhibited reduced recognition of activated PKD, the
apparent decrease in PKD protein levels observed in re-
sponse to both elevated [Ca2þ ]e and 1,25(OH)2D3 could be
interpreted as an actual decrease in PKD protein levels or
an increase in PKD activation. In order to determine which
of these alternate events occurred, the effects of elevated
[Ca2þ ]e-induced keratinocyte differentiation on PKD protein
levels were re-evaluated using the CS-2052 antibody. The
subsequent experiments focused on the effects of elevated
[Ca2þ ]e rather than 1,25(OH)2D3 because of greater and
more consistent effects of this differentiating agent. Western
blot analyses were performed on samples obtained from
primary keratinocytes incubated in SFKM (25 mM CaCl2) or
SFKM containing 1 mM CaCl2 using CS-2052 and CS-2051
to analyze changes in PKD protein levels and auto-
phosphorylation/activation status, respectively (Fig 5B).
The technique of enhanced chemifluorescence (ECF) was
used to quantitatively measure the changes observed. To
investigate the effects of calcium-induced differentiation on
PKD activity, PKD was immunoprecipitated from keratin-
ocyte cultures incubated for 10 min or 16 h in SFKM (25 mM
CaCl2) or SFKM containing 1 mM CaCl2 using CS-2052, and
in vitro kinase assays were performed. The changes in PKD
protein levels and serine 916 phosphorylation were meas-
ured at the time points of 8, 16, and 24 h because these
time points encompass the rising phase (8 h), the maximal
observed transglutaminase activity (16 h), and the plateau
phase (24 h) after stimulation with 1 mM CaCl2 (Fig 5A).
These time points also correspond to the previous report
that elevated [Ca2þ ]e (1 mM) treatment inhibits the prolif-
erative response of keratinocytes as shown by the signif-
icant and maximal inhibition of DNA sythesis after 8 and
24-h calcium treatments, respectively (Bollag et al, 1994).
The data indicate that PKD protein levels and serine 916
phosphorylation were significantly downmodulated after 8,
16, and 24 h of elevated [Ca2þ ]e treatment when compared
with control (Fig 5B,C). Also, significant decreases in PKD
activity were discovered in cultures treated with 1 mM
CaCl2 for 16 h (Fig 5D). These results are consistent with our
hypothesis that PKD is pro-proliferative and/or anti-differ-
entiative; therefore, agents, like elevated [Ca2þ ]e, that trig-
ger keratinocytes to differentiate also decrease PKD protein
expression and/or activation.
TPA treatment of keratinocytes induces a biphasic
response in terms of DNA-specific activity and trans-
glutaminase activity consistent with an initiation of
differentiation followed by proliferation TPA is known
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Figure 5
Elevated extracellular calcium stim-
ulates transglutaminase activity and
induces a downmodulation of pro-
tein kinase D (PKD) protein levels,
serine 916 autophosphorylation, and
activity. (A) Primary keratinocytes
were incubated for 8, 16, 24, or 32 h
in serum-free keratinocyte medium
(SFKM) (25 mM CaCl2) (solid line) or
SFKM containing 1 mM CaCl2 (dashed
line). The samples were collected and
transglutaminase activity assays were
performed by incubating cell sonicates
overnight in a reaction mixture con-
taining [3H]-putrescine and dimethyl-
casein, followed by precipitating the
cross-linked product and collecting by
filtration. The cpm of the radiolabeled
product were determined using liquid
scintillation spectrometry, and data
were normalized to protein content
and were analyzed using Instat 2.0.
Values represent the means  stand-
ard error of the mean (SEM) from three
experiments and were analyzed by
ANOVA with significance at po0.05
(). (B,C) Primary keratinocytes were
incubated for 8, 16, or 24 h in SFKM
(25 mM CaCl2) (lanes 1, 3, and 5, open
bars) or SFKM containing 1 mM CaCl2
(lanes 2, 4, and 6, hatched bars, striped
bars). After lysis and collection, samples were loaded according to protein concentration and subjected to western blot analysis. The immuno-
reactive signals were obtained using either CS-2052 (PKD, hatched bars) or CS-2051 (Phospho-PKD S916, striped bars) and a secondary antibody
conjugated with alkaline phosphatase. (B) The signals were visualized using a Storm Phosphorimager and (C) were quantified by ImageQuant
software and expressed relative to actin levels. Values represent the means  SEM from five to six separate experiments versus the respective
matched control and were analyzed by a Student’s t test with significance at po0.05 (). (D) Primary keratinocytes were incubated for 10 min or 16 h
in SFKM (25 mM CaCl2) (open bars) or SFKM containing 1 mM CaCl2 (striped bars), and PKD was immunoprecipitated using CS-2052 and protein-A
agarose. The immunoprecipitate was incubated with syntide-2 in the presence of [g-32P]adenosine triphosphate, and the resulting phosphorylation
was measured in a scintillation counter. Values represent the means  SEM from three separate experiments versus the respective matched control
and were analyzed by a Student’s t test with significance at po0.05 ().
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to stimulate a biphasic response in keratinocytes, with
acute treatment inducing differentiation and chronic treat-
ment stimulating proliferation in vitro (Yuspa et al, 1982a) or
tumor promotion in vivo in conjunction with a carcinogen
(Goerttler et al, 1979). Some of these previous studies were
performed under slightly different culture conditions (i.e.,
containing serum) (Yuspa et al, 1982a). To confirm the
biphasic nature of the TPA response in our system, near-
confluent keratinocytes were incubated in SFKM (25 mM
CaCl2) containing vehicle control (0.005% DMSO) or 100 nM
TPA for 8, 24, 48, and 72 h and assayed for both DNA-
specific activity, as a measure of proliferation, and trans-
glutaminase activity, as a measure of differentiation. As
expected, significant increases in transglutaminase activity
were observed after acute TPA treatment (8 h) while signif-
icant reductions were observed after chronic TPA treat-
ments (48 and 72 h) (Fig 6). Conversely, a reduction in DNA
synthesis below that of the vehicle control was observed
after acute TPA treatment (8 h), whereas significant increas-
es occurred after chronic TPA treatment (Fig 6). These data
demonstrate the ability of acute TPA treatment to induce
differentiation and of chronic TPA treatment to stimulate
proliferation in our system.
Treatment of keratinocytes with TPA induces biphasic
changes in PKD protein levels, serine 916 auto-
phosphorylation and activity PKD protein levels were
downmodulated upon keratinocyte differentiation induced
by elevated [Ca2þ ]e treatment. These results support our
hypothesis that in keratinocytes, PKD is a pro-proliferative
and/or anti-differentiative enzyme that may require down-
modulation to allow differentiation to proceed. To determine
whether the results are specific to elevated [Ca2þ ]e-induced
differentiation or also characteristic of TPA-induced differ-
entiation, the effects of acute and chronic TPA treatments
on PKD protein expression and activation were examined.
Specifically, near-confluent primary mouse keratinocytes
were incubated in SFKM (25 mM CaCl2) containing vehicle
(0.005% DMSO) or 100 nM TPA for 1, 8, 16, 24, and 48 h,
and western analyses were performed using CS-2052 to
detect PKD protein levels and CS-2051 to detect auto-
phosphorylation. To investigate the effects of acute and
chronic TPA treatments on PKD activity, PKD was immuno-
precipitated from keratinocyte cultures incubated for 1, 16,
and 48 h in SFKM (25 mM CaCl2) containing vehicle (0.005%
DMSO) or 100 nM TPA using CS-2052, and in vitro kinase
assays were performed. There were significant increases in
serine 916 autophosphorylation after 1 h of TPA treatment
and significant reductions in autophosphorylation at 8, 16,
and 24 h post-treatment (Fig 7). Interestingly, the PKD pro-
tein levels were significantly reduced to 69%  7.8% after
8 h of acute TPA treatment (Fig 7A,B), and this time point
correlates with maximal transglutaminase activity and min-
imal DNA-specific activity observed following acute TPA-
stimulated differentiation (Fig 6). After 48 h of TPA treat-
ment, PKD protein levels and serine 916 autophosphorylat-
ion recovered to values similar to those of control (Fig 7A,B).
Furthermore, PKD activity was significantly increased after
1 h of TPA treatment, significantly decreased after 16 h of
TPA treatment, and recovered to that of control after 48 h of
TPA treatment (Fig 7C). These results suggest that differ-
entiation in response to acute TPA also decreases PKD
protein levels, autophosphorylation status and activity, con-
sistent with our idea that the pro-proliferative and/or anti-
differentiative signal of PKD may need to be downmodu-
lated during differentiation in keratinocytes.
PKD protein distribution in neonatal mouse epidermis is
highest in the stratum basalis In order to investigate
whether PKD is present in the proliferative layers of the ep-
idermis, immunohistochemical analyses of PKD protein ex-
pression were performed on neonatal mouse epidermis
using the PKD-specific primary antibodies, SC-935, which
targets the C-terminus, and SC-638, which targets the
N-terminus. Unfortunately, CS-2052 is not suitable for
immunohistochemical analysis. Both SC-935 and SC-638
antibodies showed similar results: although PKD was de-
tected in suprabasal layers, PKD protein levels were great-
est in the basal layer of the epidermis, the proliferative layer
(Fig 8). These results correlate with the previous findings of
Rennecke et al (1999) that PKD expression is highest in the
proliferating cell nuclear antigen-expressing fraction of cells
isolated from mouse epidermis and are consistent with the
hypothesis that PKD is a pro-proliferative and/or anti-dif-
ferentiative signal in keratinocytes.
Co-expression of PKD has a pro-proliferative and anti-
differentiative effect on the maturation status of kera-
tinocytes as evidenced by an increase in keratin 5 pro-
moter activity and decrease in involucrin promoter
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Figure 6
12-O-tetradecanoylphorbol-13-acetate (TPA) stimulates a biphasic
response of differentiation followed by proliferation as monitored
using DNA-specific activity and transglutaminase activity. Primary
keratinocytes were incubated for 8, 24, 48, or 72 h in serum-free ker-
atinocyte medium containing vehicle (0.005% dimethyl sulfoxide) (solid
line) or 100 nM TPA (large dashed line, small dashed line). The DNA-
specific activity assay (large dashed line) was performed by incubating
cultures with 1 mCi per mL [3H]-thymidine for 1 h after treatment and
solubilizing the DNA. [3H]-Thymidine incorporation was measured in a
scintillation counter whereas DNA concentrations were determined us-
ing Hoescht dye, and values were calculated as described in Exper-
imental Procedures. The transglutaminase activity assay (small dashed
line) was performed by incubating cell sonicates overnight in a reaction
mixture containing [3H]-putrescine and dimethylcasein, followed by
precipitating the cross-linked product and collecting by filtration. The
cpm of the radiolabeled product were determined using liquid scintil-
lation spectrometry, and data were normalized to protein content. Val-
ues represent the means  standard error of the mean from at least
three experiments of either assay and were analyzed by ANOVA with
significance at po0.05 ().
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activity To test the effects of PKD on the maturation status
of keratinocytes, the promoter activities of well-established
markers of proliferation and differentiation were monitored
following PKD co-expression using the dual-luciferase as-
say. In various transfection experiments using several differ-
ent protocols and reagents (including TransIT Keratinocyte),
the maximal transfection efficiency observed for primary
mouse keratinocytes was about 10%–20%. Therefore, to
circumvent the low transfection efficiency, the dual-lucif-
erase assay was used to obtain data from the small pop-
ulation of transfected cells. The empty vector or PKD
expression vector is co-transfected with constructs in
which the keratin 5 or involucrin promoter drives the ex-
pression of firefly luciferase, which is used as a reporter to
quantify the promoter activities. Keratin 5 is expressed in
the basal layer of the epidermis and is a marker of the pro-
liferative stage of the keratinocyte life cycle (Byrne et al,
1994; Fuchs, 1995). Conversely, involucrin, a marker for in-
termediate-to-late differentiation in keratinocytes, begins to
be expressed in the upper spinous layer and increases in
expression as cells migrate upward toward the stratum
corneum (Banks-Schlegel and Green, 1981; Warhol et al,
1985). A transfection control is provided by co-transfecting
an expression construct in which the Renilla luciferase gene
is under the control of the SV40 promoter, which does not
Figure8
Protein kinase D (PKD) predominates in the stratum basalis of neo-
natal mouse epidermis. Shown here are representative tissue sections,
prepared as described in the Methods section, that demonstrate the
immunohistochemical distribution of PKD protein expression in newborn
murine epidermis. (A) The epidermis was incubated and stained using
SC-638, which targets the N-terminus of PKD. (B) The epidermis was
incubated and stained using SC-935, which recognizes the C-terminus
of PKD. (C) The negative control was obtained by incubating sections
with the secondary biotinylated antibody only. Abbreviations used are as
follows: sc, stratum corneum; sg, stratum granulosum; ss, stratum
spinosum; sb, stratum basalis. Scale bar¼50 mm.
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Figure 7
12-O-tetradecanoylphorbol-13-acetate (TPA) induces biphasic
changes in protein kinase D (PKD) protein levels, serine 916 au-
tophosphorylation, and activity. Primary keratinocytes were incubat-
ed for 1, 8, 16, 24, or 48 h in serum-free keratinocyte medium (SFKM)
containing vehicle (0.005% dimethyl sulfoxide (DMSO)) (lanes 1, 3, 5, 7,
and 9, open bars) or 100 nM TPA (lanes 2, 4, 6, 8, and 10, hatched bars,
striped bars). After lysis and collection, samples were loaded according
to protein concentration and subjected to western blot analysis. (A,B)
The immunoreactive signals obtained using either CS-2052 (PKD,
hatched bars) or CS-2051 (Phospho-PKD S916, striped bars) and a
secondary antibody conjugated with alkaline phosphatase (A) were
visualized using a Storm Phosphorimager and (B) were quantified by
ImageQuant software and expressed in Panel B relative to actin levels.
Values represent the means  standard error of the mean (SEM) from
four to six experiments versus the respective matched control and were
analyzed by a Student’s t test with significance at po0.05 (). (C) PKD
was immunoprecipitated using CS-2052 and protein-A agarose. The
immunoprecipitate was incubated with syntide-2 in the presence of
[g-32P]adenosine triphosphate, and the resulting phosphorylation was
measured in a scintillation counter. Values represent the means  SEM
from three experiments versus the respective matched control and
were analyzed by a Student’s t test with significance at po0.05 ().
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respond to calcium (Xie and Bikle, 1997). Prior to transfect-
ion, the three constructs: (1) 1 mg of the pcDNA3 or PKD
expression construct; (2) 1 mg of the keratin 5 or involucrin–
firefly luciferase construct; and (3) 0.25 mg of the control
SV40–Renilla luciferase construct (pRL–SV40), are thor-
oughly mixed. Thorough mixing increases the likelihood that
cells that are transfected with the reporter construct are
also transfected with the pcDNA3 or PKD expression con-
struct and the pRL–SV40 control construct. In addition, the
control Renilla construct is present at only one-quarter of
the amount of the other two vectors, which renders the
possibility unlikely that a cell could be transfected with only
the control construct and not at least one of the other two
constructs. Finally, the data are expressed as a ratio of
firefly luciferase activity to Renilla luciferase activity. In the
unlikely event that the cells become transfected with the
reporter vector but not the PKD expression vector or vice
versa, such scenarios would lead to an underestimation of
the maturation state changes resulting from the expression
of exogenous PKD. Co-expression of PKD significantly
increased keratin 5 promoter activity by 90%  10.4%
and significantly reduced involucrin promoter activity by
43%  2.3% (Fig 9A) when compared with co-expression
of pcDNA3 (control). These data suggest that PKD is a pro-
proliferative and anti-differentiative signal in keratinocytes.
In addition to testing the effects of PKD co-expression
under basal conditions, the effects of PKD co-expression
on keratinocyte maturation status were also examined un-
der differentiating conditions (i.e., elevated [Ca2þ ]e). Thus,
keratinocytes were transfected with each of the three con-
structs and were incubated in SFKM containing 1 mM CaCl2
for 24-h post-transfection. As expected, elevated [Ca2þ ]e
stimulated differentiation as shown by the significant re-
duction of keratin 5 promoter activity by 24%  4.1% and
significant increase of involucrin promoter activity by
500%  61.5% in cultures co-expressing pcDNA3 (data
not shown). Interestingly, when PKD was co-expressed in
cultures treated with elevated [Ca2þ ]e, keratin 5 promoter
activity was increased by 32%  11.7% above that found in
elevated [Ca2þ ]e-treated cultures co-expressing pcDNA3
(Fig 9B). Conversely, when PKD was co-expressed in cul-
tures treated with elevated [Ca2þ ]e, involucrin promoter
activity was significantly decreased by 32%  4.7% when
compared with elevated [Ca2þ ]e-treated vector-trans-
formed cells (Fig 9B). Thus, PKD co-expression opposed
the elevated [Ca2þ ]e-induced differentiation effects on both
keratin 5 and involucrin promoter activities. These data
suggest that PKD is a pro-proliferative and anti-differentia-
tive signal in keratinocytes even in the presence of the dif-
ferentiating signal of elevated [Ca2þ ]e.
Discussion
Data in the literature suggest that PKD is involved in mito-
genesis in multiple systems, including keratinocytes (Abedi
et al, 1998; Chiu and Rozengurt, 2001; Guha et al, 2002; Tan
et al, 2003; Yuan et al, 2003; Bollag et al, 2004; Kam and
Exton, 2004; Sinnett-Smith et al, 2004). Therefore, our lab-
oratory investigated the role that PKD plays in keratinocyte
maturation by analyzing the changes in PKD protein levels,
autophosphorylation, and activity in response to differenti-
ating and proliferating agents. We hypothesized that PKD is
a pro-proliferative/anti-differentiative signal in keratinocytes,
which may require downmodulation to allow differentiation
to proceed.
Initial observations using the SC-935 antibody suggested
that PKD levels were downmodulated following induction
of keratinocyte differentiation in response to 24-h elevated
[Ca2þ ]e and 1,25(OH)2D3 treatments. Western analyses with
SC-935 also demonstrated reduced PKD protein levels fol-
lowing 10-min TPA treatments. But western analyses using
the CS-2052 antibody, unlike analyses with the SC-935 an-
tibody, showed no reduction in PKD protein levels after 10-
min TPA-treatment, suggesting that the recognition of PKD
by the SC-935 antibody is reduced once PKD is activated/
autophosphorylated. Specifically, the autophosphorylation
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Figure9
Co-expression of protein kinase D (PKD) stimulates keratin 5 pro-
moter activity but inhibits involucrin promoter activity. Primary ker-
atinocytes were co-transfected with three constructs: (1) pcDNA3
control vector (open bar) or pcDNA3–PKD expression construct
(hatched bar, striped bar); (2) firefly–luciferase reporter construct un-
der control of the minimal promoter of keratin 5 (hatched bar) or in-
volucrin (striped bar); and (3) pRL–SV40 Renilla luciferase construct
under control of the SV40 promoter, which serves as an internal
transfection control. Cells were harvested after 48 h following the
transfections and 24 h following exposure to (A) basal conditions or (B)
differentiating conditions (i.e., 1 mM CaCl2). After lysis, the resulting
luciferase activity was measured in a luminometer. Values represent the
means  standard error of the mean from four keratin 5 and three in-
volucrin experiments and were analyzed by ANOVA with significance at
po0.05 ().
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status and activity of PKD were increased following 10-min
acute TPA-treatment as verified by western analyses
with the CS-2051 antibody and in vitro kinase assays,
respectively.
After validating the experimental design, the changes in
PKD were monitored upon induction of keratinocyte differ-
entiation. Because the effects of 1,25(OH)2D3 on keratin-
ocyte maturation were more variable, potentially because of
both genomic and non-genomic effects, we focused on the
effects of elevated [Ca2þ ]e. Elevated [Ca
2þ ]e is known to
induce keratinocyte differentiation in situ (Hennings et al,
1980), and this was verified in our system by a time course
analysis of transglutaminase activity after 8, 16, and 24 h of
1 mM CaCl2 treatments. It should be noted that transgluta-
minase is a marker of late differentiation because although it
is expressed first in the spinous layer, its activity is regulated
at the levels of transcription, post-transcription, and post-
translation (Gibson et al, 1996) and is maximal in the gran-
ular layer (Buxman and Wuepper, 1975). Western analyses
showed that PKD protein levels and serine 916 auto-
phosphorylation were downmodulated after 8-, 16-, and 24-
h treatments with elevated [Ca2þ ]e. Immunoprecipitation
followed by in vitro kinase assays showed that PKD activity
was downmodulated after 16 h but not after 10 min of el-
evated [Ca2þ ]e treatment, and this 16-h time point coincid-
ed with the time of maximal observed transglutaminase
activity in response to elevated [Ca2þ ]e (Fig 5). Because
PKD lacks the C2 domains that are necessary for calcium
binding and are found in classical PKC, we believe that the
downmodulation of PKD is because of the calcium-induced
differentiation and not because of direct binding of calcium.
Although the reductions of PKD protein levels, auto-
phosphorylation, and activity were statistically significant
following elevated [Ca2þ ]e treatment, the changes were
small, within the range of 20%–30%. PKD, however, is
known to associate with specific cellular compartments;
thus, global changes in protein levels, phosphorylation and
activity may not be reflective of the events occurring in a
critical site within the cell. Future analyses of changes within
particular compartments (e.g., the nucleus or the Golgi ap-
paratus) might yield more information as to the specific
regulation of PKD in response to keratinocyte maturation.
Next, the effects of TPA-induced differentiation and pro-
liferation on PKD were monitored in order to determine
whether the downmodulation of PKD is specific to calcium-
induced differentiation or whether it occurs during keratin-
ocyte differentiation in general. Previous reports by Yuspa
et al (1982a) describe the biphasic effects of TPA on ker-
atinocyte differentiation and proliferation in situ, and this
shift from differentiation to proliferation occurred well after
24 h.This early work, however, was performed in the pres-
ence of serum. In our system, keratinocytes were incubated
with TPA in low calcium concentrations (25 mM CaCl2) in the
absence of serum, and our results identify the shift from
differentiation to proliferation as occurring between 16 and
24 h. Specifically, an acute 8-h TPA treatment stimulated
transglutaminase activity to 184%  10.3% of control while
causing a reduction of DNA-specific activity below that of
control. Conversely, by 24-h, DNA-specific activity was in-
creased to 238%  29.1% of control whereas transgluta-
minase activity was reduced below that of control between
24 and 48 h. These data are consistent with the model
that acute TPA treatment promotes differentiation but that
chronic TPA treatment enhances proliferation.
Once the experimental system was validated in terms of
TPA inducing a biphasic response of differentiation followed
by proliferation in keratinocytes, we focused on the effects
of differentiation and proliferation on PKD protein levels,
autophosphorylation, and activity. Because of direct binding
of TPA to the C1 domain, PKD autophosphorylation of se-
rine 916 and enzymatic activity were stimulated following
TPA treatments of 10 min and 1 h. Corresponding with TPA-
induced differentiation, PKD levels were downmodulated
after an 8-h treatment but not after exposure times of 10 min
to 1 h, consistent with the findings of Rennecke et al (1996).
Furthermore, PKD autophosphorylation was significantly
reduced below that of control after 8, 16, and 24 h of TPA
treatment, with a corresponding decrease in PKD activity
after 16 h of TPA treatment. We believe that PKD down-
modulation occurs as a result of the differentiative effects of
acute TPA treatment and not as a result of a direct-binding
effect or proteolytic degradation by the tumor promoter.
Chronic TPA treatment, which results in keratinocyte pro-
liferation, resulted in recovery of PKD protein levels, auto-
phosphorylation status and activity to those of control. Why
these values did not increase significantly above control is
somewhat puzzling given the proliferative response at these
times (Fig 7); however, it may be related to timing and/or
experimental limitations in the sensitivity of the western blot
analyses and in vitro kinase assays.
PKD1 is the first member of a family of protein kinases
that now also includes PKD2 and PKD3/PKCn. Comparative
western analyses using the four commercially available
PKD-specific antibodies described in this work definitively
showed that each antibody produces a strong immunore-
active signal corresponding to PKD1 overexpression (Fig 3).
All three family members, however, share a similar domain
structure with some sequence homology (Rykx et al, 2003),
and the SC-935 antibody, a C-terminal-specific PKD anti-
body, has been reported to cross-react with PKD2 in west-
ern analyses (Sturany et al, 2001). In addition, the phospho-
PKD/PKCm Ser744-Ser748 antibody, which is directed
against the serines located in the activation loop, cross-
reacts with all three members (Rey et al, 2003). At this point,
we are unsure whether the CS-2052 or CS-2051 antibodies
cross-react with other PKD family members and are actively
investigating the role of PKD2 in keratinocyte maturation.
Although neither PKD2 nor PKD3 have been reported in
keratinocytes, we have detected PKD2 expression by RT-
PCR analysis in RNA isolated from our primary keratin-
ocytes (unpublished results). Our results concerning PKD
protein levels and autophosphorylation are thought to re-
flect the changes in PKD1, but because of the limitations of
antibody specificity, changes in PKD2 and/or PKD3 may
also contribute to the observed effects.
The epidermis is a stratified epithelium, and cellular lo-
calization within the epidermal tissue is indicative of mat-
uration status. Therefore, immunohistochemical analysis
was utilized to discern whether the expression pattern of
PKD corresponded with the proliferative keratinocytes. Two
separate antibodies, SC-638 and SC-935, which target the
N- and C-terminus, respectively, produced staining patterns
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indicating that PKD protein expression was highest in the
basal layer, the layer consisting of proliferating progenitor
cells. Because similar staining was observed with two dif-
ferent PKD-specific antibodies, we believe that the results
accurately depict the expression pattern of PKD. This stain-
ing pattern is consistent with our hypothesis that PKD has a
pro-proliferative and/or anti-differentiative role in keratin-
ocytes. Interestingly, both antibodies also labeled the nu-
clear compartment, which is consistent with reports that
PKD, as well PKD3, can translocate to the nucleus (Rey
et al, 2001, 2003).
Finally, the effect of PKD on keratinocyte maturation was
tested by co-expression studies under basal (25 mM cal-
cium) and differentiating conditions (1 mM calcium) using
the keratin 5 and involucrin promoters as markers of pro-
liferation and differentiation, respectively. Under basal con-
ditions, PKD co-expression enhanced the promoter activity
of keratin 5 and reduced the promoter activity of involucrin.
Under differentiating conditions, PKD co-expression op-
posed the effects of elevated [Ca2þ ]e, also increasing the
promoter activity of keratin 5 and reducing the promoter
activity of involucrin when compared with calcium-treated
cultures co-transfected with pcDNA3. In this experiment,
we have used the dual-luciferase assay in a novel way to
monitor changes in keratinocyte maturation in response to
PKD co-expression. Although there are reports that PKD
can directly phosphorylate c-Jun (Hurd et al, 2002) and hi-
stone deacetylase (Vega et al, 2004), which could affect
transcription, we believe that PKD is affecting the matura-
tion status of keratinocytes, thereby modulating the pro-
moter activities of keratin 5 and involucrin and not by
directly influencing the promoter activities of keratin 5 or
involucrin. These data suggest that PKD acts as a pro-pro-
liferative and anti-differentiative signal in keratinocytes and
are consistent with our proposed hypothesis. These data
also support the need for further research into the potential
role of PKD in the tumor-promoting effects of phorbol esters
on keratinocytes.
Materials and Methods
Materials Calcium-free minimum essential medium (MEMa) was
from Biologos (Montgomery, Illinois), and ITSþ (insulin, transferrin,
selenous acid, linoleic acid) was from Collaborative Biomedical
Products (Bedford, Massachusetts). 1,25(OH)2D3 was a generous
gift from Dr Maurice Pechet (Harvard, Cambridge, Massachusetts).
TPA, Hoechst 33258 dye, calf-thymus DNA and the secondary
antibodies, goat anti-rabbit conjugated with alkaline phosphatase
and rabbit anti-goat conjugated with alkaline phosphatase, were
from Sigma (St Louis, Missouri). DC protein assay reagents were
from Bio-Rad (Hercules, California). Bovine serum albumin (BSA)
was from Pierce (Rockford, Illinois), and Immobilon-P polyvinyli-
dene difluoride (PVDF) membrane was from Millipore (Billerica,
Massachusetts). Opti-MEM and Lipofectin were from Invitrogen
(Carlsbad, California). Dulbecco’s modification of Eagle’s medium
(DMEMþ 4.5 g per liter of glucose) was from Fisher Scientific
(Hampton, New Hampshire). In addition to the ABC Immunohisto-
chemistry detection system, the following antibodies were from
Santa Cruz Biotech (Santa Cruz, California): the anti-PKD antibod-
ies, SC-638 and SC-935; the anti-actin antibody, SC-1616; the
protein-A agarose-conjugated antibody, SC-2001; and the horse-
radish peroxidase (HRP)-conjugated goat anti-rabbit antibody, SC-
2004. The anti-phospho-PKD S916 antibody, CS-2051, and the
anti-PKD antibody, CS-2052, were from Cell Signaling Technology
(Beverly, Massachusetts). O.C.T.4583 compound was from Sakura
Finetek USA (Torrance, California), and 125I-labeled goat anti-rabbit
secondary antibody was from Amersham Biosciences (Piscataway,
New Jersey). Hematoxylin solution was from Richard-Allan Scien-
tific (Kalamazoo, Michigan), and Permount was from Biomedia
(Foster City, California). TransIT-Keratinocyte transfection reagent
was from Mirus (Madison, Wisconsin). P-81 paper and GF/A glass
microfiber filter circles were from Whatman (Clifton, New Jersey).
PKD was cloned from CBA mouse brain cDNA using PCR and was
subcloned into the pcDNA3 expression vector. The pRL–SV40
construct was included in the Dual-Luciferase Reporter assay kit
from Promega (Madison, Wisconsin). Dr Bogi Andersen (University
of California, San Diego, California) kindly provided the keratin 5–
luciferase construct (Sugihara et al, 2001) while Dr Daniel Bikle
(University of California, San Francisco, California) kindly provided
the involucrin–luciferase construct (Ng et al, 1996).
Keratinocyte culture Primary epidermal keratinocytes were pre-
pared from 1- to 3-d-old neonatal ICR mice by first removing the
skins as single sheets. After incubating the mouse skins in 0.25%
trypsin overnight at 41C, the epidermis and dermis were mechan-
ically separated using forceps, and cells were released by gentle
scraping. The cells were then collected by centrifugation and plat-
ed at a density of 25,000 cells per cm2 in six-well tissue-culture
plates in plating medium consisting of calcium-free MEM a sup-
plemented with 2% dialyzed fetal bovine serum (FBS), 25 mM
CaCl2, 5 ng per mL epidermal growth factor, 2 mM glutamine,
ITSþ , 100 U per mL of penicillin, 100 mg per mL streptomycin, and
0.25 mg per mL fungizone. After approximately 24 h, the plating
media was replaced with SFKM containing 25 mM CaCl2, 90 mg per
mL bovine pituitary extract, ITSþ , 5 ng per mL epidermal growth
factor, 2 mM glutamine, 0.05% BSA, 100 U per mL penicillin, 100
mg per mL streptomycin, and 0.25 mg per mL fungizone. The media
was replaced with fresh SFKM every 1–2 d. All animal studies were
performed using protocols approved by the institutional animal
care and use committee.
Western blot analysis Near-confluent (60%–80%) cultures of
keratinocytes were incubated in SFKM (25 mM CaCl2) containing
vehicle (0.05% ethanol, 0.1% DMSO, or 0.005% DMSO) or the
indicated treatment: 1 mM CaCl2, 250 nM 1,25(OH)2D3, or 100 nM
TPA. The cells were then harvested at the desired time points by
washing once with phosphate-buffered saline lacking divalent cat-
ions (PBS), followed by the addition of 300 mL of heated lysis
buffer (0.1875 M Tris-HCl (pH 8.5), 3% sodium dodecyl sulfide
(SDS), 1.5 mM ethylenediaminetetraacetic acid (EDTA)). Thirty mi-
croliters of lysate was used to determine protein concentration
using the DC protein assay with BSA as the standard, and 270 mL
of the lysate was added to 135 mL of 3  sample buffer (30%
glycerol, 15% b-mercaptoethanol, 1% bromophenol blue) to con-
stitute Laemmli buffer (Laemmli, 1970). Samples were stored at
701C until western analysis was performed. After boiling, equal
protein amounts from each sample were loaded, separated by
electrophoresis through 8% SDS polyacrylamide gels, and trans-
ferred to PVDF membrane. Membranes were incubated in blocking
buffer (0.1% Tween-20, 4% milk in PBS or Tris-buffered saline
(TBS; 10 mM Tris, 150 mM NaCl, pH 8)) prior to incubation at 41C in
blocking buffer containing one of the following primary antibodies:
rabbit anti-human PKD, SC-935 (1:500); and rabbit anti-mouse
PKD, CS-2052 (1:1000); rabbit anti-mouse phospho-PKD S916,
CS-2051 (1:1000), or goat anti-human actin (I-19), SC-1616
(1:1000). After washing in PBS/0.1% Tween-20 solution or TBS/
0.1% Tween-20 solution, the membranes were incubated for 1–2 h
in blocking buffer containing one of the following secondary an-
tibodies: 125I-labeled goat anti-rabbit (0.1 mCi per mL or 1:500);
goat anti-rabbit conjugated with HRP, SC-2004 (1:1000); goat anti-
rabbit conjugated with alkaline phosphatase (1:7500) or rabbit
anti-goat conjugated with alkaline phosphatase (1:30,000). Immuno-
reactive bands corresponding to the proteins of interest were
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visualized by enhanced chemiluminescence using film or by
autoradiography (125I) or ECF using a Phosphorimager SI (Molec-
ular Dynamics, Sunnyvale, California) or a Storm Phosphorimager
(Molecular Dynamics), respectively. Immunoreactive signals were
quantified using ImageQuant software (Molecular Dynamics), and
the data reported were normalized according to actin levels.
COS-7 transfection COS-7 cells were grown to 40%–60% con-
fluence in 60-mm dishes in 10% FBS/DMEM and were transfected
with 6 mg per dish of pcDNA3 or pcDNA3–PKD. Transfections were
performed using 2 mL per dish of Opti-MEM and 10 mL per dish of
Lipofectin as described in the manufacturer’s protocol. After 5 h of
incubation in transfection mix, 2 mL of 10% FBS/Opti-MEM was
added to each dish. After 72 h of incubation, cells were scraped in
heated lysis buffer and were subjected to western analysis as de-
scribed above using the PKD-specific antibodies (SC-935, SC-
638, CS-2052, and CS-2051) and the actin-specific antibody (I-19).
Equal amounts of protein (10 mg) from each sample were loaded in
quadruplicate, and actin was used to verify equal loading.
In vitro kinase assay Near-confluent cultures of primary keratin-
ocytes were incubated in SFKM (25 mM CaCl2) or SFKM containing
1 mM CaCl2, vehicle (0.1% DMSO or 0.005% DMSO), or 100 nM
TPA for the desired time periods at 371C. Cells were scraped in
immunoprecipitation buffer [50 mM Tris-HCl (pH 7.4), 2 mM eth-
yleneglycoltetraacetic acid, 2 mM EDTA, 1 mM dithiothreitol, 10 mg
per mL aprotinin, 10 mg per mL leupeptin, 1 mM 4-(2-aminoethyl)-
benzenesulfonyl fluoride hydrochloride, and 1% Triton-X 100] and
disrupted by sonication. Thirty microliters of lysates were used to
determine protein concentration prior to immunoprecipitation.
Equal protein amounts were precleared with protein-A agarose
(SC-2001; 1:250) to remove any proteins that may immunoprecip-
itate because of non-specific binding. PKD was then immuno-
precipitated using both SC-638 (1:200) and SC-935 (1:200) or
CS-2052 alone followed by incubation with protein-A agarose
(1:250) at 41C. The immunoprecipitates were washed twice, re-
suspended in 30 mL of kinase buffer (30 mM Tris-HCl (pH 7.6),
10 mM MgCl2, 1 mM dithiothreitol) and incubated with 2.5 mg per
mL (1.66 mM) syntide-2, 100 mM ATP, and 10 mCi [g-32P]ATP at
301C for 10 min. The reactions were terminated by the addition of
350 mM H3PO4 (final concentration) and were spotted onto P-81
paper. Finally, the P-81 papers were washed in 75 mM H3PO4 and
dried overnight. The radioactivity was quantified using an LS 6500
scintillation counter (Beckman Coultier, Fullerton, California).
Transglutaminase assay Transglutaminase activity assays were
performed as described (Griner et al, 1999). Briefly, cultures of
primary keratinocytes were incubated in SFKM (25 mM CaCl2) or
SFKM containing 1 mM CaCl2, vehicle (0.005% DMSO), or 100 nM
TPA for the desired time periods. Subsequently, intact cells were
harvested, and transglutaminase activity was measured according
to the method of Folk and Chung (1985) with minor modifications.
Specifically, dimethylcasein was substituted for a-casein, and re-
actions were permitted to continue overnight before ice-cold
trichloroacetic acid was used to precipitate the [3H]-putrescine/
dimethylcasein cross-linked product onto GF/A glass microfiber
filter circles. The cpm of the radiolabeled products were deter-
mined using liquid scintillation spectrometry, and data were nor-
malized to protein content.
DNA-specific assay The DNA-specific assay was performed as
described (Bollag et al, 1993). Briefly, cultures of primary keratin-
ocytes were incubated in SFKM (25 mM CaCl2) containing vehicle
(0.005% DMSO) or 100 nM TPA for the indicated duration followed
by incubation with 1 mCi per mL [3H]-thymidine for 1 h at 371C.
Cells were harvested by scraping, washed, and resuspended in
500 mL of PEN buffer (0.05 M NaH2PO4/Na2HPO4 (pH 7.4), 2 mM
EDTA, and 2 M NaCl). Samples were stored at 201C until all time
points were collected. Samples were thawed and sonicated on ice,
and unbroken cells were pelleted by centrifugation. The supernat-
ant containing the solubilized DNA was recovered, and a 200 mL
aliquot was subjected to liquid scintillation spectrometry. A second
aliquot was used to quantify the DNA concentration of the samples
using 0.1 mg per mL Hoechst 33258 dye and calf-thymus DNA as
the standard. Finally, the DNA-specific activity of each sample was
expressed as average dpm multiplied by 2.5 and divided by the
DNA concentration ((average dpm  5/2)/DNA concentration) to
represent the total DNA-specific activity of each well.
Immunohistochemistry Murine epidermal samples were harvest-
ed following sacrifice, in compliance with animal care and use com-
mittee guidelines. The tissue specimens were quick-frozen in
O.C.T.4583 compound in a dry ice/isopentane bath, cryosectioned
onto glass microscope slides, and stored at 701C until analysis.
The ABC immunohistochemistry detection system was used for the
analysis of 7 mm-thick transverse cryostat sections. Cryostat sections
were fixed in cold acetone, followed by the quenching of endog-
enous peroxidases by incubation in 3% H2O2/PBS and the block-
ing of non-specific binding sites by incubation in 5% goat serum/
PBS. The sections were incubated with primary antibody, SC-935
(1:200) or SC-638 (1:200), followed by incubation with a biotinylated
secondary antibody, SC-2018 (1:200). Samples were immersed in the
ABC reagent to allow binding of avidin to the biotinylated secondary
antibody and binding of biotinylated HRP to the avidin. The target
protein was visualized by incubation of samples in the diaminobu-
tane-chromogen, which produces a distinctive brown stain. Nuclei
were counterstained with a hematoxylin solution, and negative con-
trols were prepared similarly, except that the primary antibody was
omitted. Finally, sections were dehydrated by immersion in solutions
with increasing concentrations of ethanol and cover slip-mounted
with Permount. Observation and imaging of stained samples was
performed using bright field analysis on a Zeiss (Carl Zeiss
International, Thornwood, New York) Axiophot microscope (magni-
fications of  10 and  20) coupled to an imaging station.
Luciferase assay PKD was cloned from CBA mouse brain cDNA
using PCR and was subcloned into the pcDNA3 expression vector.
Sub-confluent (  30%) cultures of primary keratinocytes in SFKM
were co-transfected with three constructs: (1) 1 mg per well of
pcDNA3 control vector or pcDNA3–PKD expression construct; (2)
1 mg per well of firefly–luciferase reporter construct under control of
the minimal promoter of keratin 5, kindly provided by Dr Bogi
Andersen (University of California, San Diego, California) (Sugihara
et al, 2001) or involucrin, kindly provided by Dr Daniel Bikle (Uni-
versity of California, San Francisco, California) (Ng et al, 1996); and
(3) 25 ng per well of pRL–SV40 Renilla luciferase construct under
control of the SV40 promoter, which serves as an internal transfect-
ion control. The constructs were mixed thoroughly prior to addition
of the transfection reagents. Transfections were performed using
the TransIT–Keratinocyte transfection reagent according to the
manufacturer’s protocol. After 24 h, the transfection media were
replaced with SFKM (25 mM CaCl2) or SFKM containing 1 mM
CaCl2, and cultures were incubated for an additional 24 h. The
luciferase assays were performed as described in the Dual-Lucif-
erase Reporter Assay protocol, and measurements were obtained
using a luminometer (Turner Designs, Sunnyvale, California). Data
are expressed as the ratio of promoter-driven firefly luciferase ex-
pression to control SV40-driven Renilla luciferase expression.
Statistical analysis The significance of differences between mean
values was determined using ANOVA with a Student–Neumann–
Keuls post hoc test or a Student’s t test with a two-tailed p value as
indicated and as performed by Instat 2.0 (GraphPad Software, San
Diego, California).
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